Skip to main content
Top

Open Access 25-04-2024 | Hemophilia

The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease

Authors: Ahmed E. Ali, Richard C. Becker

Published in: Journal of Thrombosis and Thrombolysis

Login to get access

Abstract

Anticoagulant therapy is a mainstay in the management of patients with cardiovascular disease and related conditions characterized by a heightened risk for thrombosis. Acute coronary syndrome, chronic coronary syndrome, ischemic stroke, and atrial fibrillation are the most common. In addition to their proclivity for thrombosis, each of these four conditions is also characterized by local and systemic inflammation, endothelial/endocardial injury and dysfunction, oxidative stress, impaired tissue-level reparative capabilities, and immune dysregulation that plays a critical role in linking molecular events, environmental triggers, and phenotypic expressions. Knowing that cardiovascular disease and thrombosis are complex and dynamic, can the scientific community identify a common pathway or specific point of interface susceptible to pharmacological inhibition or alteration that is likely to be safe and effective? The contact factors of coagulation may represent the proverbial “sweet spot” and are worthy of investigation. The following review provides a summary of the fundamental biochemistry of factor XI, its biological activity in thrombosis, inflammation, and angiogenesis, new targeting drugs, and a pragmatic approach to managing hemostatic requirements in clinical trials and possibly day-to-day patient care in the future.
Literature
3.
go back to reference Bouma BN, Griffin JH (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252(18):6432–6437CrossRefPubMed Bouma BN, Griffin JH (1977) Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. J Biol Chem 252(18):6432–6437CrossRefPubMed
5.
go back to reference Walsh PN, Sinha D, Koshy A, Seaman FS, Bradford H (1986) Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. Blood 68(1):225–230CrossRefPubMed Walsh PN, Sinha D, Koshy A, Seaman FS, Bradford H (1986) Functional characterization of platelet-bound factor XIa: retention of factor XIa activity on the platelet surface. Blood 68(1):225–230CrossRefPubMed
18.
go back to reference Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134(5):1087–1097PubMedPubMedCentral Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134(5):1087–1097PubMedPubMedCentral
21.
go back to reference Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104(15):6388-6393.https://doi.org/10.1073/pnas.0608647104 Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Günther A, Engelmann B, Preissner KT (2007) Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 104(15):6388-6393.https://​doi.​org/​10.​1073/​pnas.​0608647104
25.
27.
go back to reference Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP (2001) Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86(4):959–972PubMed Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP (2001) Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 86(4):959–972PubMed
29.
30.
go back to reference Ameri A, Kuppuswamy MN, Basu S, Bajaj SP (1992) Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79(12):3219–3226CrossRefPubMed Ameri A, Kuppuswamy MN, Basu S, Bajaj SP (1992) Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79(12):3219–3226CrossRefPubMed
32.
go back to reference Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, Hazen SL, Petersen JL, Reist CJ, Kleiman NS (2011) Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis 31(2):146–153. https://doi.org/10.1007/s11239-010-0532-yCrossRefPubMed Becker RC, Mahaffey KW, Yang H, Marian AJ, Furman MI, Michael Lincoff A, Hazen SL, Petersen JL, Reist CJ, Kleiman NS (2011) Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. J Thromb Thrombolysis 31(2):146–153. https://​doi.​org/​10.​1007/​s11239-010-0532-yCrossRefPubMed
35.
go back to reference MacDonald S, White D, Langdown J, Downes K, Thomas W (2020) Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. Int J Lab Hematol 42(3):246–255. https://doi.org/10.1111/ijlh.13155CrossRefPubMed MacDonald S, White D, Langdown J, Downes K, Thomas W (2020) Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity. Int J Lab Hematol 42(3):246–255. https://​doi.​org/​10.​1111/​ijlh.​13155CrossRefPubMed
36.
39.
go back to reference Patel-Hett S, Martin EJ, Mohammed BM, Rakhe S, Sun P, Barrett JC, Nolte ME, Kuhn J, Pittman DD, Murphy JE, Brophy DF (2019) Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia 25(5):797–806. https://doi.org/10.1111/hae.13820CrossRefPubMed Patel-Hett S, Martin EJ, Mohammed BM, Rakhe S, Sun P, Barrett JC, Nolte ME, Kuhn J, Pittman DD, Murphy JE, Brophy DF (2019) Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia 25(5):797–806. https://​doi.​org/​10.​1111/​hae.​13820CrossRefPubMed
43.
go back to reference Sainz IM, Pixley RA, Colman RW (2007) Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 98(1):77–83CrossRefPubMed Sainz IM, Pixley RA, Colman RW (2007) Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 98(1):77–83CrossRefPubMed
44.
go back to reference Pallares Robles A, Ten Cate V, Schulz A, Prochaska JH, Rapp S, Koeck T, Panova-Noeva M, Heitmeier S, Schwers S, Leineweber K, Seyfarth HJ, Opitz CF, Spronk H, Espinola-Klein C, Lackner KJ, Münzel T, Andrade-Navarro MA, Konstantinides SV, Ten Cate H, Wild PS (2022) Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Sci Rep 12(1):9761. https://doi.org/10.1038/s41598-022-13174-5CrossRefPubMedPubMedCentral Pallares Robles A, Ten Cate V, Schulz A, Prochaska JH, Rapp S, Koeck T, Panova-Noeva M, Heitmeier S, Schwers S, Leineweber K, Seyfarth HJ, Opitz CF, Spronk H, Espinola-Klein C, Lackner KJ, Münzel T, Andrade-Navarro MA, Konstantinides SV, Ten Cate H, Wild PS (2022) Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis. Sci Rep 12(1):9761. https://​doi.​org/​10.​1038/​s41598-022-13174-5CrossRefPubMedPubMedCentral
48.
go back to reference Jordan KR, Wyatt CR, Fallon ME, Woltjer R, Neuwelt EA, Cheng Q, Gailani D, Lorentz C, Tucker EI, McCarty OJT, Hinds MT, Nguyen KP (2022) Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis. J Thromb Haemost 20(9):2035–2045. https://doi.org/10.1111/jth.15777CrossRefPubMedPubMedCentral Jordan KR, Wyatt CR, Fallon ME, Woltjer R, Neuwelt EA, Cheng Q, Gailani D, Lorentz C, Tucker EI, McCarty OJT, Hinds MT, Nguyen KP (2022) Pharmacological reduction of coagulation factor XI reduces macrophage accumulation and accelerates deep vein thrombosis resolution in a mouse model of venous thrombosis. J Thromb Haemost 20(9):2035–2045. https://​doi.​org/​10.​1111/​jth.​15777CrossRefPubMedPubMedCentral
51.
go back to reference Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, Hinds MT, Fazio S, Monia BP, Gailani D, Gruber A, Tavori H, McCarty OJT (2021) Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost 19(4):1001–1017. https://doi.org/10.1111/jth.15236CrossRefPubMedPubMedCentral Ngo ATP, Jordan KR, Mueller PA, Hagen MW, Reitsma SE, Puy C, Revenko AS, Lorentz CU, Tucker EI, Cheng Q, Hinds MT, Fazio S, Monia BP, Gailani D, Gruber A, Tavori H, McCarty OJT (2021) Pharmacological targeting of coagulation factor XI mitigates the development of experimental atherosclerosis in low-density lipoprotein receptor-deficient mice. J Thromb Haemost 19(4):1001–1017. https://​doi.​org/​10.​1111/​jth.​15236CrossRefPubMedPubMedCentral
56.
go back to reference Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AWA, Bethune C, Morgan E, Yu RZ, Wang Y, Jung SW, Geary R, Bhanot S (2021) PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst Pharmacol 10(8):890–901. https://doi.org/10.1002/psp4.12663CrossRefPubMedPubMedCentral Willmann S, Marostica E, Snelder N, Solms A, Jensen M, Lobmeyer M, Lensing AWA, Bethune C, Morgan E, Yu RZ, Wang Y, Jung SW, Geary R, Bhanot S (2021) PK/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients. CPT Pharmacometrics Syst Pharmacol 10(8):890–901. https://​doi.​org/​10.​1002/​psp4.​12663CrossRefPubMedPubMedCentral
63.
go back to reference Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, ... Hart RG (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400(10357):997–1007. https://doi.org/10.1016/s0140-6736(22)01588-4 Shoamanesh A, Mundl H, Smith EE, Masjuan J, Milanov I, Hirano T, Agafina A, Campbell B, Caso V, Mas JL, Dong Q, Turcani P, Christensen H, Ferro JM, Veltkamp R, Mikulik R, De Marchis GM, Robinson T, Lemmens R, ... Hart RG (2022) Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet 400(10357):997–1007. https://​doi.​org/​10.​1016/​s0140-6736(22)01588-4
66.
go back to reference Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA (2018) First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol 84(5):876–887. https://doi.org/10.1111/bcp.13520CrossRefPubMedPubMedCentral Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA (2018) First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. Br J Clin Pharmacol 84(5):876–887. https://​doi.​org/​10.​1111/​bcp.​13520CrossRefPubMedPubMedCentral
77.
go back to reference Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399(10333):1383–1390. https://doi.org/10.1016/s0140-6736(22)00456-1CrossRefPubMed Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR (2022) Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet 399(10333):1383–1390. https://​doi.​org/​10.​1016/​s0140-6736(22)00456-1CrossRefPubMed
78.
go back to reference Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ (2022) Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 31(10):106742. https://doi.org/10.1016/j.jstrokecerebrovasdis.2022.106742CrossRefPubMedPubMedCentral Sharma M, Molina CA, Toyoda K, Bereczki D, Kasner SE, Lutsep HL, Tsivgoulis G, Ntaios G, Czlonkowska A, Shuaib A, Amarenco P, Endres M, Diener HC, Gailani D, Kahl A, Donovan M, Perera V, Li D, Hankey GJ (2022) Rationale and design of the AXIOMATIC-SSP phase II trial: antithrombotic treatment with factor XIa inhibition to optimize management of acute thromboembolic events for secondary stroke prevention. J Stroke Cerebrovasc Dis 31(10):106742. https://​doi.​org/​10.​1016/​j.​jstrokecerebrova​sdis.​2022.​106742CrossRefPubMedPubMedCentral
79.
go back to reference Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 146(16):1196–1206. https://doi.org/10.1161/circulationaha.122.061612CrossRefPubMed Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH (2022) A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction. Circulation 146(16):1196–1206. https://​doi.​org/​10.​1161/​circulationaha.​122.​061612CrossRefPubMed
85.
go back to reference Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J (2015) Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia 21(4):481–489. https://doi.org/10.1111/hae.12655CrossRefPubMedPubMedCentral Bauduer F, de Raucourt E, Boyer-Neumann C, Trossaert M, Beurrier P, Faradji A, Peynet J, Borg JY, Chamouni P, Chatelanaz C, Henriet C, Bridey F, Goudemand J (2015) Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia 21(4):481–489. https://​doi.​org/​10.​1111/​hae.​12655CrossRefPubMedPubMedCentral
90.
go back to reference Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61-65PubMed Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61-65PubMed
Metadata
Title
The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease
Authors
Ahmed E. Ali
Richard C. Becker
Publication date
25-04-2024
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-024-02985-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare